Mild asthma does not interfere with the progression of pregnancy and the prognosis for mother and child is good. Short-acting inhaled β2-agonists are recommended for symptom control. Salbutamol is the preferred short-acting inhaled β2-agonist because it is very safe. There is no evidence of fetal damage from the use of short-acting inhaled beta2-agonists, and there is no evidence to contraindicate the use of such drugs during breastfeeding. The preferred long-term control medication is a daily inhaled low-dose glucocorticoid. A large body of data suggests that this drug is safe and effective in pregnant women with asthma, with no increased risk of adverse perinatal regression. Budesonide is the preferred inhaled glucocorticosteroid because more data are available on its use in pregnant women than on other inhaled glucocorticosteroids. It should be noted that there are no data to suggest that other inhaled glucocorticoid preparations are unsafe during pregnancy. Therefore, for inhaled glucocorticosteroids other than budesonide, if the patient’s asthma is well controlled with these agents prior to pregnancy, they may continue to be used. If asthma cannot be brought under control, choose a low-dose inhaled glucocorticoid plus a long-acting inhaled β2-agonist or increase the dose of inhaled glucocorticoid to a moderate dose.